BlossomHill Therapeutics, Inc. Common Stock Total Liabilities
BlossomHill Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, BlossomHill Therapeutics, Inc. Common Stock (BLSM) has total liabilities worth $295.53 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BLSM working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of BlossomHill Therapeutics, Inc. Common Stock (2024–2025)
Total liabilities of BlossomHill Therapeutics, Inc. Common Stock from 2024 to 2025. This chart illustrates how BlossomHill Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
BlossomHill Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of BlossomHill Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Moso Power Supply Technology Co Ltd
SHE:002660
|
China | CN¥838.53 Million |
|
KT Submarine Co. Ltd
KQ:060370
|
Korea | ₩79.71 Billion |
|
Avidia Bancorp, Inc.
NYSE:AVBC
|
USA | $2.42 Billion |
|
Digital Network S.A.
WAR:DIG
|
Poland | zł241.63 Million |
|
Korea Petro Chemical Ind
KO:006650
|
Korea | ₩618.86 Billion |
|
Gran Tierra Energy Inc
TO:GTE
|
Canada | CA$1.43 Billion |
|
Sofwave Medical Ltd
TA:SOFW
|
Israel | ILA22.97 Million |
|
Alpha Hpa Ltd
AU:A4N
|
Australia | AU$103.83 Million |
Liability Composition Analysis (2024–2025)
This chart breaks down BlossomHill Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BlossomHill Therapeutics, Inc. Common St assets under control.
Liquidity & Leverage Metrics
BlossomHill Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
BlossomHill Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BlossomHill Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BlossomHill Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of BlossomHill Therapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $294.70 Million | +64.03% |
| 2024-12-31 | $179.66 Million | -- |
About BlossomHill Therapeutics, Inc. Common Stock
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients w… Read more